Legend Biotech's CAR-T Therapy Carvykti Surges with 95.9% Growth, Reaching Nearly $1.9 Billion in 2025 Sales

Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted must be authorized.

January 21,Johnson & JohnsonLifePublicCloth2025Year-roundFinanceReport, The financial report shows that 2025Total annual revenue reached $94.2 billion, a year-on-year increase of 6%. Among this, the two core business segments—innovative pharmaceuticals and medical technology—generated revenues of $60.401 billion (+6%) and $33.792 billion (+6.1%), respectively.

Legend Biotech's Collaboration with Johnson & JohnsonCAR-T Star Product Carvykti(Cilta-cel) sets astonishing records:Global sales reached $1.887 billion, a year-on-year surge of 95.9%.; becoming the world's second-largest CAR-T product, with a solid monopoly in the second-line treatment market; Johnson & Johnson has even forecasted sales of $3 billion by 2026, aiming for a peak of $10 billion.

Thanks to the expansion of CAR-T production capacity by Johnson & Johnson and Legend Biotech in recent years,The advancement of frontline treatments and the growth of the global market share,Carvykti's sales are growing rapidly, andBecoming the world's best-selling CAR-T drug.

In fact,Carvykti's sales growth has basically doubled year by year.

Carvykti was approved for marketing by the FDA in February 2022; its sales revenue in the first year of 2022 was $134 million, with $500 million in 2023, $963 million in 2024, and $1.887 billion in 2025. Based on the current growth trend, Carvykti is expected to achieve total sales of $3 billion by 2026.

In addition, based on the sales volume in 2024, Gilead SciencesYescarta is the CAR-T product with the highest global sales (Sales in 2024 were$1.57 billion）。

But according toFrom the sales trend of Yescarta in the first three quarters of this year,Carvykti is expected to surpassYescarta Becomes the New Peak of CAR-T Annual Sales.

ReferenceReference Materials:

Company Financial Report